Skip to content
Screener

Cash & Equivalents at other companies

Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$274.5M+35.8%
Corcept Therapeutics logo
Corcept TherapeuticsCORT
$112.29M+9.3%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$882.02M+62.5%
MBX Biosciences, Inc. logo
MBX Biosciences, Inc.MBX
$45.21M+51.2%
XER
Xeris Biopharma Holdings, Inc.XERS
$121.75M+105%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$118.12M+211%

Other financials

Income statement

See full
Revenue$10.7M+2,873%
Gross profit$10.5M+2,818%
Operating income-$140.4M-26.0%
Net income-$127.8M-32.1%
EPS (diluted)-$1.23-18.3%

Balance sheet

See full
Total debt$47.9M-5.8%
Total equity$1.3B+2.1%
Total assets$1.4B+2.9%

Cash flow

See full
Operating cash flow-$124.7M-41.0%
CapEx$820.0K-33.8%
Free cash flow-$125.5M-40.0%

Valuation

See full
Market cap$8.9B+233%
Enterprise value$8.84B+231%
P/S492.8×-1,427×

Profitability

See full
Gross margin150%-15.6pp
Operating margin-3,020.3%-1,463pp
Net margin-2,747.2%-1,328pp
FCF margin-2,321.7%-1,122pp

Returns & leverage

See full
Return on equity-39.2%+14.5pp
Debt / equity0.0×
Current ratio18.6×-3.9×

Where this comes from

Reported directly by Crinetics Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:21 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001658247-26-000040
Line itemThree months ended / March 31, 2026Three months ended / March 31, 2025
Net change in cash, cash equivalents and restricted cash12,813(169,976)
Exchange rate changes in cash, cash equivalents and restricted cash(8)
Cash, cash equivalents and restricted cash - beginning of period102,336265,845
Cash, cash equivalents and restricted cash - end of period$115,141$95,869
COMPONENTS OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH
Cash and cash equivalents$114,341$94,569
Restricted cash8001,300
Cash, cash equivalents and restricted cash at end of period$115,141$95,869

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Crinetics Pharmaceuticals's cash & equivalents?
Crinetics Pharmaceuticals (CRNX) reported cash & equivalents of $115.14M in Q1 2026.
How has Crinetics Pharmaceuticals's cash & equivalents changed year-over-year?
Crinetics Pharmaceuticals's cash & equivalents increased by 20.1% year-over-year, from $95.87M to $115.14M.
What is the long-term trend for Crinetics Pharmaceuticals's cash & equivalents?
Over 5 years (2020 to 2025), Crinetics Pharmaceuticals's cash & equivalents has grown at a 1.9% compound annual growth rate (CAGR), from $93.09M to $102.34M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Crinetics Pharmaceuticals's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude